Liquid pharmaceutical compositions of baclofen for oral administration

A stable pharmaceutical solution comprising:

• a) 2 mg/mL or more baclofen;
• b) at least one crystallization inhibitor;
• and
• c) at least one pharmaceutically acceptable liquid vehicle;
• wherein the crystallization inhibitor is selected from the group consisting of polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), hydroxyethyl cellulose (HEC), xylitol, and mixtures thereof,
• wherein the solution is in the form of a ready-to-use or a ready-to-administer stable solution that is suitable for oral administration to a subject in need thereof,
• wherein the solution does not contain cyclodextrin or cyclodextrin derivatives, and
• wherein a weight ratio of the crystallization inhibitor to the baclofen ranges from about 1:1 to 25:1.

A stable pharmaceutical solution comprising:

• a) 2 mg/mL or more baclofen;
• b) at least one crystallization inhibitor;
• and
• c) at least one pharmaceutically acceptable liquid vehicle;
• wherein the crystallization inhibitor comprises hydroxypropyl methyl cellulose (HPMC) in combination with at least one additional crystallization inhibitor selected from the group consisting of polyvinylpyrrolidone (PVP), hydroxyethyl cellulose (HEC), xylitol, and mixtures thereof,
• wherein the solution is in the form of a ready-to-use or a ready-to-administer stable solution that is suitable for oral administration to a subject in need thereof, and
• wherein the solution does not contain cyclodextrin or cyclodextrin derivatives.